Bio tech company updates — 8/28/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Samsung Biologics announced a massive capital raise to fund a peptide manufacturing acquisition, while KOTRA facilitated a major partnership event connecting over 120 Korean biotech firms with Mayo Clinic. Additionally, the Ministry of Food and Drug Safety outlined new regulatory accelerations, and Ceragem joined the national Brain-Computer Interface Alliance.
Key Findings
- Samsung Biologics Capital Raise: Samsung Biologics plans to raise over 3 trillion won ($2.2 billion) via rights issue to acquire a peptide manufacturer and build new production capacity.
- Mayo Clinic Partnership: KOTRA hosted the "Mayo Clinic-DMC Partnership Day," bringing together more than 120 Korean bio-health companies to discuss global clinical trials and US market entry.
- Regulatory Updates: The Ministry of Food and Drug Safety (MFDS) announced measures to accelerate innovation in the bio-sector, focusing on faster approval processes for cutting-edge therapies.
- BCI Alliance Expansion: Healthcare device maker Ceragem has joined Korea’s BCI Alliance to collaborate on brain-computer interface technologies with academia and hospitals.
Details
Samsung Biologics Expands into Peptide Manufacturing
In a significant move to diversify its contract development and manufacturing organization (CDMO) capabilities, Samsung Biologics announced on August 28 that it will raise over 3 trillion won through a rights issue. The capital is earmarked for the acquisition of a peptide manufacturer and the construction of a new production plant, signaling a strategic pivot toward high-demand peptide-based therapeutics alongside its existing antibody business.
KOTRA Facilitates Mayo Clinic Collaboration
The Korea Trade-Investment Promotion Agency (KOTRA) organized a two-day event titled "Mayo Clinic-DMC Partnership Day," which concluded recently. The event gathered over 120 Korean bio-health companies with representatives from the Mayo Clinic and Dongguk Medical Center (DMC). The primary focus was on facilitating global clinical trials and helping Korean firms navigate the regulatory landscape for entry into the United States market.
MFDS Accelerates Bio Innovation
The Ministry of Food and Drug Safety (MFDS), led by Minister Oh Yu-Kyoung, released statements detailing new initiatives to accelerate the pace of innovation in the biotechnology sector. These measures aim to support the "great leap" in bio-technology by streamlining regulatory frameworks and fostering an environment conducive to rapid development of next-generation bio-products.
Ceragem Joins National BCI Alliance
Ceragem, known for its health-tech devices, has officially joined Korea's Brain-Computer Interface (BCI) Alliance. This alliance serves as a collaborative platform linking industry players, academic institutions, research institutes, and hospitals. Ceragem's participation aims to accelerate the development of future healthcare technologies by leveraging BCI innovations for therapeutic and diagnostic applications.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
